Bicara Therapeutics (BCAX)
Bicara Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
10.3M
Short interest
settlement 2026-10-15
11.5
Days to cover
-2.7 days vs prior
19.3%
Short share of volume
2026-11-02
267
Fails to deliver
settlement 2026-10-14
Mon 9 Nov
Next earnings
estimated date
-$1.6M
Insider flow, 90 days
0 buys, 5 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in BCAX is 10,298,207 shares, down 893,517 shares over the last month. Over the last 48 readings it ranged from 1,690,473 shares (31 October 2024) to 11,191,724 shares (15 September 2026). The latest reading sits at the top of that range. At the reported average volume of 893K shares a day that is 11.5 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/bcax" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 10,298,207 | -3.7% | 893,322 | 11.53 |
| 2026-09-30 | 10,693,490 | -4.5% | 753,208 | 14.20 |
| 2026-09-15 | 11,191,724 | +3.2% | 496,027 | 22.56 |
| 2026-08-31 | 10,845,514 | +3.6% | 491,104 | 22.08 |
| 2026-08-14 | 10,463,188 | +9.0% | 787,826 | 13.28 |
| 2026-07-31 | 9,597,404 | +3.0% | 469,965 | 20.42 |
| 2026-07-15 | 9,315,906 | -8.0% | 734,248 | 12.69 |
| 2026-06-30 | 10,121,649 | -0.4% | 1,379,948 | 7.33 |
| 2026-06-15 | 10,160,393 | +0.8% | 514,104 | 19.76 |
| 2026-05-29 | 10,083,302 | +2.4% | 448,419 | 22.49 |
| 2026-05-15 | 9,849,290 | +10.7% | 568,908 | 17.31 |
| 2026-04-30 | 8,896,472 | -4.6% | 416,640 | 21.35 |
| 2026-04-15 | 9,325,843 | -3.3% | 635,652 | 14.67 |
| 2026-03-31 | 9,639,901 | +3.0% | 584,655 | 16.49 |
| 2026-03-13 | 9,360,506 | +1.0% | 619,145 | 15.12 |
| 2026-02-27 | 9,268,841 | +5.2% | 625,891 | 14.81 |
| 2026-02-13 | 8,813,695 | -1.0% | 328,208 | 26.85 |
| 2026-01-30 | 8,899,892 | -0.1% | 412,290 | 21.59 |
| 2026-01-15 | 8,909,119 | -2.6% | 473,791 | 18.80 |
| 2025-12-31 | 9,148,792 | +14.1% | 609,485 | 15.01 |
| 2025-12-15 | 8,018,780 | +4.8% | 654,522 | 12.25 |
| 2025-11-28 | 7,655,080 | +6.0% | 753,847 | 10.15 |
| 2025-11-14 | 7,218,989 | +11.8% | 676,594 | 10.67 |
| 2025-10-31 | 6,457,982 | +13.7% | 804,282 | 8.03 |
| 2025-10-15 | 5,679,088 | +4.1% | 652,051 | 8.71 |
| 2025-09-30 | 5,457,251 | -3.7% | 693,238 | 7.87 |
| 2025-09-15 | 5,669,220 | +5.1% | 280,437 | 20.22 |
| 2025-08-29 | 5,392,258 | -1.3% | 276,637 | 19.49 |
| 2025-08-15 | 5,460,303 | -2.3% | 315,609 | 17.30 |
| 2025-07-31 | 5,588,503 | -1.0% | 293,996 | 19.01 |
| 2025-07-15 | 5,644,328 | -1.6% | 441,535 | 12.78 |
| 2025-06-30 | 5,737,266 | +12.8% | 928,428 | 6.18 |
| 2025-06-13 | 5,084,728 | -22.7% | 1,232,551 | 4.13 |
| 2025-05-30 | 6,578,158 | -11.3% | 1,506,707 | 4.37 |
| 2025-05-15 | 7,417,157 | +14.2% | 634,957 | 11.68 |
| 2025-04-30 | 6,495,930 | +20.5% | 566,624 | 11.46 |
| 2025-04-15 | 5,391,114 | +1.6% | 495,095 | 10.89 |
| 2025-03-31 | 5,307,960 | +5.2% | 487,852 | 10.88 |
| 2025-03-14 | 5,046,885 | -10.0% | 735,039 | 6.87 |
| 2025-02-28 | 5,607,873 | +34.5% | 405,418 | 13.83 |
| 2025-02-14 | 4,168,259 | +2.2% | 247,181 | 16.86 |
| 2025-01-31 | 4,077,688 | -4.0% | 404,031 | 10.09 |
| 2025-01-15 | 4,248,213 | -6.0% | 391,258 | 10.86 |
| 2024-12-31 | 4,520,580 | +49.3% | 780,926 | 5.79 |
| 2024-12-13 | 3,028,320 | +29.0% | 326,140 | 9.29 |
| 2024-11-29 | 2,347,100 | +13.2% | 364,852 | 6.43 |
| 2024-11-15 | 2,072,645 | +22.6% | 288,289 | 7.19 |
| 2024-10-31 | 1,690,473 | +29.7% | 297,249 | 5.69 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of BCAX volume is 19.3%, down 19.0 points over the last five sessions. Over the last 30 readings it ranged from 18.7% (22 September 2026) to 64.1% (9 October 2026). The latest reading sits at the bottom of that range. The latest reading is 24.2 points below the 30-session average of 43.5%, on 1.0M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 199K | 1.0M | 19.3% | 4,092 |
| 2026-10-30 | 413K | 1.6M | 26.1% | 900 |
| 2026-10-29 | 442K | 1.5M | 30.5% | 17,854 |
| 2026-10-28 | 2.0M | 7.1M | 28.3% | 147,854 |
| 2026-10-27 | 109K | 239K | 45.7% | 0 |
| 2026-10-26 | 188K | 491K | 38.3% | 0 |
| 2026-10-23 | 147K | 267K | 54.9% | 0 |
| 2026-10-22 | 166K | 340K | 48.9% | 0 |
| 2026-10-21 | 149K | 241K | 61.7% | 15,598 |
| 2026-10-20 | 65K | 165K | 39.3% | 0 |
| 2026-10-19 | 111K | 358K | 31.1% | 0 |
| 2026-10-16 | 181K | 294K | 61.6% | 0 |
| 2026-10-15 | 106K | 200K | 52.8% | 0 |
| 2026-10-14 | 310K | 532K | 58.3% | 0 |
| 2026-10-13 | 246K | 569K | 43.1% | 0 |
| 2026-10-12 | 162K | 266K | 60.8% | 0 |
| 2026-10-09 | 205K | 320K | 64.1% | 0 |
| 2026-10-08 | 376K | 641K | 58.6% | 0 |
| 2026-10-07 | 126K | 389K | 32.3% | 0 |
| 2026-10-06 | 183K | 426K | 42.9% | 0 |
| 2026-10-05 | 95K | 250K | 37.8% | 0 |
| 2026-10-02 | 90K | 229K | 39.2% | 0 |
| 2026-10-01 | 95K | 207K | 45.8% | 0 |
| 2026-09-30 | 130K | 319K | 40.6% | 5,500 |
| 2026-09-29 | 122K | 194K | 62.8% | 0 |
| 2026-09-28 | 112K | 264K | 42.4% | 0 |
| 2026-09-25 | 125K | 239K | 52.2% | 0 |
| 2026-09-24 | 197K | 699K | 28.2% | 4,662 |
| 2026-09-23 | 243K | 635K | 38.3% | 0 |
| 2026-09-22 | 55K | 292K | 18.7% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in BCAX is 267 shares, down 2,031 shares over the last settlement date. Over the last 30 readings it ranged from 3 shares (15 July 2026) to 32,200 shares (11 August 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 267 | $17.34 | $5K |
| 2026-10-09 | 2,298 | $17.26 | $40K |
| 2026-09-28 | 326 | $19.21 | $6K |
| 2026-09-25 | 326 | $19.78 | $6K |
| 2026-09-18 | 2,564 | $22.59 | $58K |
| 2026-09-17 | 8 | $22.00 | $176 |
| 2026-09-16 | 25 | $22.67 | $567 |
| 2026-09-03 | 1,614 | $23.56 | $38K |
| 2026-08-12 | 18 | $23.76 | $428 |
| 2026-08-11 | 32,200 | $27.73 | $893K |
| 2026-08-07 | 1,718 | $27.51 | $47K |
| 2026-08-06 | 2,411 | $25.89 | $62K |
| 2026-08-03 | 48 | $27.10 | $1K |
| 2026-07-29 | 3,887 | $26.88 | $104K |
| 2026-07-27 | 2,096 | $27.02 | $57K |
| 2026-07-16 | 140 | $28.12 | $4K |
| 2026-07-15 | 3 | $28.10 | $84 |
| 2026-06-30 | 7,379 | $29.34 | $216K |
| 2026-06-29 | 1,095 | $26.87 | $29K |
| 2026-06-26 | 54 | $26.34 | $1K |
| 2026-06-22 | 17 | $23.23 | $395 |
| 2026-06-17 | 3,077 | $21.95 | $68K |
| 2026-06-15 | 23,822 | $21.69 | $517K |
| 2026-06-12 | 23,800 | $21.28 | $506K |
| 2026-06-10 | 256 | $20.56 | $5K |
| 2026-06-08 | 3,787 | $20.00 | $76K |
| 2026-06-04 | 171 | $20.00 | $3K |
| 2026-05-18 | 6,313 | $20.23 | $128K |
| 2026-05-08 | 21,400 | $23.09 | $494K |
| 2026-04-29 | 81 | $21.92 | $2K |
Insider trades
SEC Form 4, newest first. JSONInsiders at BCAX reported 5 open-market sells worth $1.6M in the last 90 days and no open-market buys. Latest filing: Cohlhepp Ryan (President, COO & Interim CEO) on 2026-09-08.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | Cohlhepp Ryan | President, COO & Interim CEO | Sell | 3K | $23.43 | $81K | 182K |
| 2026-09-08 | Cohlhepp Ryan | President, COO & Interim CEO | Sell | 14K | $22.77 | $320K | 185K |
| 2026-09-08 | Cohlhepp Ryan | President, COO & Interim CEO | Exercise or conversion | 18K | $3.79 | $66K | 199K |
| 2026-08-10 | Hyep Ivan | Chief Financial Officer | Sell | 13K | $27.97 | $350K | 130K |
| 2026-08-10 | Hyep Ivan | Chief Financial Officer | Exercise or conversion | 13K | $3.79 | $47K | 142K |
| 2026-08-10 | Mazumdar Claire | Chief Executive Officer | Sell | 10K | $27.98 | $280K | 362K |
| 2026-08-10 | Mazumdar Claire | Chief Executive Officer | Exercise or conversion | 10K | $3.79 | $38K | 372K |
| 2026-08-10 | Cohlhepp Ryan | President and COO | Sell | 19K | $27.98 | $525K | 182K |
| 2026-08-10 | Cohlhepp Ryan | President and COO | Exercise or conversion | 19K | $3.79 | $71K | 200K |
| 2026-07-10 | Mazumdar Claire | Chief Executive Officer | Sell | 28 | $29.68 | $831 | 362K |
| 2026-07-10 | Mazumdar Claire | Chief Executive Officer | Sell | 10K | $28.42 | $283K | 362K |
| 2026-07-10 | Mazumdar Claire | Chief Executive Officer | Exercise or conversion | 10K | $3.79 | $38K | 372K |
| 2026-07-09 | Cohlhepp Ryan | President and COO | Sell | 536 | $29.00 | $16K | 182K |
| 2026-07-08 | Cohlhepp Ryan | President and COO | Sell | 1K | $30.35 | $33K | 182K |
| 2026-07-08 | Cohlhepp Ryan | President and COO | Sell | 4K | $29.80 | $128K | 183K |
| 2026-07-08 | Cohlhepp Ryan | President and COO | Sell | 23K | $28.76 | $657K | 188K |
| 2026-07-08 | Cohlhepp Ryan | President and COO | Exercise or conversion | 19K | $3.79 | $71K | 210K |
| 2026-07-08 | Hyep Ivan | Chief Financial Officer | Sell | 830 | $30.31 | $25K | 130K |
| 2026-07-08 | Hyep Ivan | Chief Financial Officer | Sell | 4K | $29.82 | $132K | 131K |
| 2026-07-08 | Hyep Ivan | Chief Financial Officer | Sell | 23K | $28.60 | $651K | 135K |
| 2026-07-08 | Hyep Ivan | Chief Financial Officer | Exercise or conversion | 13K | $3.79 | $47K | 158K |
| 2026-05-21 | Hyep Ivan | Chief Financial Officer | Sell | 9K | $20.42 | $188K | 145K |
| 2026-05-21 | Hyep Ivan | Chief Financial Officer | Exercise or conversion | 9K | $3.79 | $35K | 155K |
| 2026-05-18 | Mazumdar Claire | Chief Executive Officer | Sell | 3K | $20.35 | $61K | 362K |
| 2026-05-18 | Mazumdar Claire | Chief Executive Officer | Sell | 12K | $19.96 | $240K | 365K |
| 2026-05-18 | Mazumdar Claire | Chief Executive Officer | Exercise or conversion | 15K | $3.79 | $57K | 377K |
| 2026-05-15 | Cohlhepp Ryan | President and COO | Sell | 5K | $20.29 | $91K | 192K |
| 2026-05-15 | Cohlhepp Ryan | President and COO | Sell | 8K | $20.29 | $162K | 196K |
| 2026-05-15 | Cohlhepp Ryan | President and COO | Exercise or conversion | 8K | $3.79 | $30K | 204K |
| 2026-04-27 | Raben David | Chief Medical Officer | Sell | 6K | $22.88 | $126K | 55K |
| 2026-04-27 | Raben David | Chief Medical Officer | Exercise or conversion | 6K | $3.79 | $21K | 61K |
| 2026-04-21 | Hyep Ivan | Chief Financial Officer | Sell | 9K | $23.00 | $212K | 145K |
| 2026-04-21 | Hyep Ivan | Chief Financial Officer | Exercise or conversion | 9K | $3.79 | $35K | 155K |
| 2026-04-20 | Mazumdar Claire | Chief Executive Officer | Sell | 15K | $23.61 | $354K | 362K |
| 2026-04-20 | Mazumdar Claire | Chief Executive Officer | Exercise or conversion | 15K | $3.79 | $57K | 377K |
| 2026-04-16 | Mazumdar Claire | Chief Executive Officer | Exercise or conversion | 7K | $5.45 | $39K | 362K |
| 2026-04-16 | Mazumdar Claire | Chief Executive Officer | Exercise or conversion | 7K | $3.79 | $28K | 355K |
| 2026-04-16 | Mazumdar Claire | Chief Executive Officer | Exercise or conversion | 8K | $4.44 | $36K | 348K |
| 2026-04-15 | Cohlhepp Ryan | President and COO | Sell | 5K | $23.01 | $104K | 196K |
| 2026-04-15 | Cohlhepp Ryan | President and COO | Sell | 8K | $23.01 | $184K | 201K |
| 2026-04-15 | Cohlhepp Ryan | President and COO | Exercise or conversion | 8K | $3.79 | $30K | 209K |
| 2026-03-25 | Raben David | Chief Medical Officer | Sell | 6K | $18.95 | $104K | 55K |
| 2026-03-25 | Raben David | Chief Medical Officer | Exercise or conversion | 6K | $3.79 | $21K | 61K |
| 2026-03-23 | Hyep Ivan | Chief Financial Officer | Sell | 9K | $18.52 | $170K | 145K |
| 2026-03-23 | Hyep Ivan | Chief Financial Officer | Exercise or conversion | 9K | $3.79 | $35K | 155K |
| 2026-03-20 | Mazumdar Claire | Chief Executive Officer | Sell | 2K | $18.95 | $30K | 339K |
| 2026-03-20 | Mazumdar Claire | Chief Executive Officer | Exercise or conversion | 2K | $3.79 | $6K | 341K |
| 2026-03-19 | Mazumdar Claire | Chief Executive Officer | Sell | 7K | $18.78 | $130K | 339K |
| 2026-03-19 | Mazumdar Claire | Chief Executive Officer | Exercise or conversion | 7K | $3.79 | $26K | 346K |
| 2026-03-18 | Mazumdar Claire | Chief Executive Officer | Sell | 6K | $18.84 | $122K | 339K |
| 2026-03-18 | Mazumdar Claire | Chief Executive Officer | Exercise or conversion | 6K | $3.79 | $25K | 346K |
| 2026-03-16 | Cohlhepp Ryan | President and COO | Sell | 5K | $19.66 | $88K | 201K |
| 2026-03-16 | Cohlhepp Ryan | President and COO | Sell | 8K | $19.66 | $157K | 205K |
| 2026-03-16 | Cohlhepp Ryan | President and COO | Exercise or conversion | 8K | $3.79 | $30K | 213K |
| 2026-03-09 | Mazumdar Claire | Chief Executive Officer | Sell | 37K | $19.17 | $705K | 339K |
| 2026-03-09 | Mazumdar Claire | Chief Executive Officer | Exercise or conversion | 37K | $3.79 | $139K | 376K |
| 2026-03-06 | Mazumdar Claire | Chief Executive Officer | Sell | 4K | $18.75 | $72K | 339K |
| 2026-03-06 | Mazumdar Claire | Chief Executive Officer | Exercise or conversion | 4K | $3.79 | $14K | 343K |
| 2026-03-05 | Mazumdar Claire | Chief Executive Officer | Sell | 2K | $18.74 | $33K | 339K |
| 2026-03-05 | Mazumdar Claire | Chief Executive Officer | Exercise or conversion | 2K | $3.79 | $7K | 341K |
| 2026-03-04 | Hyep Ivan | Chief Financial Officer | Sell | 3K | $18.25 | $54K | 145K |
| 2026-03-04 | Hyep Ivan | Chief Financial Officer | Exercise or conversion | 3K | $3.79 | $11K | 148K |
| 2026-03-04 | Raben David | Chief Medical Officer | Sell | 16K | $18.52 | $302K | 55K |
| 2026-03-04 | Raben David | Chief Medical Officer | Exercise or conversion | 16K | $3.79 | $62K | 72K |
| 2026-03-04 | Mazumdar Claire | Chief Executive Officer | Sell | 3K | $18.73 | $49K | 339K |
| 2026-03-04 | Mazumdar Claire | Chief Executive Officer | Exercise or conversion | 3K | $3.79 | $10K | 342K |
| 2026-03-03 | Cohlhepp Ryan | President and COO | Sell | 5K | $18.16 | $82K | 205K |
| 2026-03-03 | Cohlhepp Ryan | President and COO | Sell | 13K | $18.16 | $234K | 210K |
| 2026-03-03 | Cohlhepp Ryan | President and COO | Exercise or conversion | 13K | $3.79 | $49K | 223K |
| 2026-03-03 | Hyep Ivan | Chief Financial Officer | Sell | 14K | $18.22 | $247K | 145K |
| 2026-03-03 | Hyep Ivan | Chief Financial Officer | Exercise or conversion | 6K | $3.79 | $24K | 159K |
| 2026-03-03 | Hyep Ivan | Chief Financial Officer | Exercise or conversion | 7K | $3.79 | $28K | 153K |
| 2026-03-03 | Raben David | Chief Medical Officer | Sell | 200 | $18.45 | $4K | 55K |
| 2026-03-03 | Raben David | Chief Medical Officer | Exercise or conversion | 200 | $3.79 | $758 | 55K |
| 2026-02-26 | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | Buy | 300K | $16.00 | $4.8M | 4.6M |
| 2026-02-25 | Cohlhepp Ryan | President and COO | Sell | 523 | $18.04 | $9K | 210K |
| 2026-02-25 | Cohlhepp Ryan | President and COO | Sell | 3K | $18.04 | $56K | 210K |
| 2026-02-25 | Cohlhepp Ryan | President and COO | Exercise or conversion | 3K | $3.79 | $12K | 213K |
| 2026-01-22 | Cohlhepp Ryan | President and COO | Sell | 4K | $18.10 | $69K | 210K |
| 2026-01-22 | Hyep Ivan | Chief Financial Officer | Sell | 2K | $18.15 | $34K | 145K |
| 2026-01-22 | Hyep Ivan | Chief Financial Officer | Exercise or conversion | 2K | $3.79 | $7K | 147K |
| 2026-01-15 | Cohlhepp Ryan | President and COO | Sell | 149 | $18.02 | $3K | 214K |
| 2025-12-26 | Cohlhepp Ryan | President and COO | Exercise or conversion | 25K | $4.44 | $111K | 214K |
| 2025-12-26 | Raben David | Chief Medical Officer | Exercise or conversion | 20K | $3.79 | $75K | 55K |
| 2025-12-22 | Hyep Ivan | Chief Financial Officer | Sell | 9K | $18.31 | $168K | 145K |
| 2025-12-22 | Hyep Ivan | Chief Financial Officer | Exercise or conversion | 9K | $3.79 | $35K | 155K |
| 2025-12-16 | Mazumdar Claire | Chief Executive Officer | Exercise or conversion | 30K | $5.45 | $161K | 339K |
| 2025-12-15 | Cohlhepp Ryan | President and COO | Sell | 5K | $18.68 | $84K | 189K |
| 2025-12-15 | Cohlhepp Ryan | President and COO | Sell | 8K | $18.68 | $149K | 194K |
| 2025-12-15 | Cohlhepp Ryan | President and COO | Exercise or conversion | 8K | $3.79 | $30K | 202K |
| 2025-11-25 | Raben David | Chief Medical Officer | Sell | 906 | $18.84 | $17K | 35K |
| 2025-11-25 | Raben David | Chief Medical Officer | Exercise or conversion | 906 | $3.79 | $3K | 36K |
| 2025-11-25 | Raben David | Chief Medical Officer | Sell | 5K | $18.84 | $87K | 35K |
| 2025-11-25 | Raben David | Chief Medical Officer | Exercise or conversion | 5K | $3.79 | $17K | 40K |
| 2025-11-24 | Raben David | Chief Medical Officer | Sell | 6K | $18.45 | $101K | 35K |
| 2025-11-24 | Raben David | Chief Medical Officer | Exercise or conversion | 6K | $3.79 | $21K | 41K |
| 2025-11-24 | Mazumdar Claire | Chief Executive Officer | Sell | 41K | $18.86 | $776K | 310K |
| 2025-11-24 | Mazumdar Claire | Chief Executive Officer | Exercise or conversion | 41K | $3.79 | $156K | 351K |
| 2025-11-24 | Hyep Ivan | Chief Financial Officer | Sell | 18K | $18.55 | $330K | 145K |
| 2025-11-24 | Hyep Ivan | Chief Financial Officer | Exercise or conversion | 18K | $3.79 | $67K | 163K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON50 Form 144 notices on file for BCAX worth $15.8M at the prices reported; 6 in the last 90 days worth $2.3M. Latest: DAVID RABEN filed on 2026-10-21 to sell 24,777 shares ($449K) from 2026-10-21.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-21 | DAVID RABENOfficer | 25K | $449K | 0.037% | 2026-10-21 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-08 | Hyep IvanOfficer | 13K | $283K | 0.019% | 2026-09-08 | UBS Financial Services, Inc. |
| 2026-09-08 | Cohlhepp RyanOfficer, Director | 18K | $396K | 0.026% | 2026-09-08 | UBS Financial Services, Inc |
| 2026-08-10 | Hyep IvanOfficer | 13K | $348K | 0.019% | 2026-08-10 | UBS Financial Services, Inc. |
| 2026-08-10 | Cohlhepp RyanOfficer, Director | 19K | $522K | 0.029% | 2026-08-10 | UBS Financial Services, Inc |
| 2026-08-10 | Mazumdar ClaireOfficer, Director | 10K | $278K | 0.015% | 2026-08-10 | UBS Financial Services, Inc. |
| 2026-07-10 | Mazumdar ClaireOfficer, Director | 10K | $297K | 0.015% | 2026-07-10 | UBS Financial Services, Inc. |
| 2026-07-08 | Cohlhepp RyanOfficer, Director | 29K | $870K | 0.044% | 2026-07-08 | UBS Financial Services, Inc |
| 2026-07-08 | Hyep IvanOfficer | 28K | $847K | 0.043% | 2026-07-08 | UBS Financial Services, Inc. |
| 2026-07-08 | DAVID RABENOfficer | 50K | $1.4M | 0.076% | 2026-07-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-07 | Lara MeisnerOfficer | 1K | $30K | 0.002% | 2026-07-07 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-25 | DAVID RABENOfficer | 50K | $1.3M | 0.076% | 2026-06-25 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-01 | Meisner LaraFormer Chief Legal Officer | 71K | $1.5M | 0.109% | 2026-06-01 | Morgan Stanley Smith Barney LLC |
| 2026-05-26 | Raben DavidOfficer | 6K | $120K | 0.008% | 2026-05-26 | UBS Financial Services Inc. |
| 2026-05-21 | Hyep IvanOfficer | 9K | $188K | 0.014% | 2026-05-21 | UBS Financial Services, Inc. |
| 2026-05-18 | Mazumdar ClaireOfficer, Director | 15K | $314K | 0.023% | 2026-05-18 | UBS Financial Services, Inc. |
| 2026-05-15 | Cohlhepp RyanOfficer, Director | 13K | $254K | 0.019% | 2026-05-15 | UBS Financial Services, Inc |
| 2026-04-27 | Raben DavidOfficer | 6K | $126K | 0.008% | 2026-04-27 | UBS Financial Services Inc. |
| 2026-04-21 | Hyep IvanOfficer | 9K | $213K | 0.014% | 2026-04-21 | UBS Financial Services, Inc. |
| 2026-04-20 | Mazumdar ClaireOfficer, Director | 15K | $356K | 0.023% | 2026-04-20 | UBS Financial Services, Inc. |
| 2026-04-15 | Cohlhepp RyanOfficer, Director | 13K | $287K | 0.019% | 2026-04-15 | UBS Financial Services, Inc |
| 2026-03-25 | Raben DavidOfficer | 6K | $104K | 0.010% | 2026-03-25 | UBS Financial Services Inc. |
| 2026-03-23 | Hyep IvanOfficer | 9K | $171K | 0.017% | 2026-03-23 | UBS Financial Services, Inc. |
| 2026-03-20 | Mazumdar ClaireOfficer, Director | 2K | $30K | 0.003% | 2026-03-20 | UBS Financial Services, Inc. |
| 2026-03-19 | Mazumdar ClaireOfficer, Director | 7K | $130K | 0.013% | 2026-03-19 | UBS Financial Services, Inc. |
| 2026-03-18 | Mazumdar ClaireOfficer, Director | 6K | $125K | 0.012% | 2026-03-18 | UBS Financial Services, Inc. |
| 2026-03-16 | Cohlhepp RyanOfficer, Director | 13K | $242K | 0.023% | 2026-03-16 | UBS Financial Services, Inc |
| 2026-03-09 | Mazumdar ClaireOfficer | 37K | $705K | 0.067% | 2026-03-09 | UBS Financial Services, Inc. |
| 2026-03-06 | Mazumdar ClaireOfficer | 4K | $76K | 0.007% | 2026-03-06 | UBS Financial Services, Inc. |
| 2026-03-05 | Mazumdar ClaireOfficer | 2K | $33K | 0.003% | 2026-03-05 | UBS Financial Services, Inc. |
| 2026-03-04 | Hyep IvanOfficer | 3K | $54K | 0.005% | 2026-03-04 | UBS Financial Services, Inc. |
| 2026-03-04 | Mazumdar ClaireOfficer | 3K | $49K | 0.005% | 2026-03-04 | UBS Financial Services, Inc. |
| 2026-03-04 | Raben DavidOfficer | 16K | $302K | 0.030% | 2026-03-04 | UBS Financial Services Inc. |
| 2026-03-03 | Hyep IvanOfficer | 14K | $247K | 0.025% | 2026-03-03 | UBS Financial Services, Inc. |
| 2026-03-03 | Raben DavidOfficer | 200 | $4K | 0.000% | 2026-03-03 | UBS Financial Services Inc. |
| 2026-03-03 | Cohlhepp RyanOfficer | 17K | $316K | 0.032% | 2026-03-03 | UBS Financial Services, Inc |
| 2026-02-25 | Cohlhepp RyanOfficer | 4K | $66K | 0.007% | 2026-02-25 | UBS Financial Services, Inc |
| 2026-01-22 | Cohlhepp RyanOfficer | 4K | $65K | 0.007% | 2026-01-22 | UBS Financial Services, Inc |
| 2026-01-22 | Hyep IvanOfficer | 2K | $34K | 0.003% | 2026-01-22 | UBS Financial Services, Inc. |
| 2026-01-15 | Cohlhepp RyanOfficer | 149 | $3K | 0.000% | 2026-01-15 | UBS Financial Services, Inc |
| 2025-12-22 | Hyep IvanOfficer | 9K | $164K | 0.017% | 2025-12-22 | UBS Financial Services, Inc. |
| 2025-12-15 | Cohlhepp RyanOfficer | 13K | $234K | 0.023% | 2025-12-15 | UBS Financial Services, Inc |
| 2025-11-25 | Raben DavidOfficer | 6K | $104K | 0.010% | 2025-11-25 | UBS Financial Services Inc. |
| 2025-11-24 | Mazumdar ClaireOfficer | 41K | $776K | 0.075% | 2025-11-24 | UBS Financial Services, Inc. |
| 2025-11-24 | Hyep IvanOfficer | 18K | $330K | 0.032% | 2025-11-24 | UBS Financial Services, Inc. |
| 2025-11-24 | Raben DavidOfficer | 6K | $101K | 0.010% | 2025-11-24 | UBS Financial Services Inc. |
| 2025-11-21 | Hyep IvanOfficer | 605 | $11K | 0.001% | 2025-11-21 | UBS Financial Services, Inc. |
| 2025-11-21 | Cohlhepp RyanOfficer | 13K | $226K | 0.023% | 2025-11-21 | UBS Financial Services, Inc |
| 2025-10-16 | Mazumdar ClaireOfficer, Director | 24K | $454K | 0.044% | 2025-10-16 | UBS Financial Services, Inc. |
| 2025-10-15 | Cohlhepp RyanOfficer | 13K | $227K | 0.023% | 2025-10-15 | UBS Financial Services, Inc |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON11 holders report 5% or more of BCAX in their latest filing, 4 on Schedule 13D (active intent). The largest reported stake is RA Capital Management, L.P. at 11.5% of the class (7,279,739 shares), filed 2026-03-02 for an event on 2026-02-26.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-07 | 13G/Ano. 2 | T. Rowe Price Investment Management, Inc.investment adviser | 2.8M | 4.2% | 2026-09-30 |
| 2026-08-13 | 13G/Ano. 1 | JANUS HENDERSON GROUP Ltd.parent holding company | 3.2M | 4.8% | 2026-06-30 |
| 2026-07-27 | 13G | BlackRock, Inc.parent holding company | 3.5M | 5.4% | 2026-06-30 |
| 2026-05-15 | 13G | JANUS HENDERSON GROUP PLCparent holding company | 3.3M | 5.1% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Deep Track Capital, LPinvestment adviser, other entity | 4.1M | 6.2% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | David Kroinparent holding company, individual | 4.1M | 6.2% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | Deep Track Biotechnology Master Fund, Ltd.corporation | 4.1M | 6.2% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 3 | Ryan Wilderparent holding company, individual | 5.4M | 8.3% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 3 | Vestal Point Capital, LPinvestment adviser, partnership | 5.4M | 8.3% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 1 | Heath Lukatchindividual | 3.2M | 4.8% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 1 | Red Tree Venture Fund, L.P.partnership | 3.2M | 4.8% | 2026-03-31 |
| 2026-05-08 | 13G/Ano. 1 | Red Tree GP, LLCother entity | 3.2M | 4.8% | 2026-03-31 |
| 2026-05-06 | 13G/Ano. 2 | FMR LLCparent holding company | 2.1M | 3.2% | 2026-03-31 |
| 2026-05-06 | 13G/Ano. 2 | Abigail P. Johnsonindividual | 2.1M | 3.2% | 2026-03-31 |
| 2026-03-02 | 13D/Ano. 1 | RA Capital Management, L.P.investment adviser, partnership | 7.3M | 11.5% | 2026-02-26 |
| 2026-03-02 | 13D/Ano. 1 | Peter Kolchinskyparent holding company, individual | 7.3M | 11.5% | 2026-02-26 |
| 2026-03-02 | 13D/Ano. 1 | Rajeev Shahparent holding company, individual | 7.3M | 11.5% | 2026-02-26 |
| 2026-03-02 | 13D/Ano. 1 | RA Capital Healthcare Fund, L.P.partnership | 4.6M | 7.3% | 2026-02-26 |
13F holders
Tracked managers holding BCAX at their latest 13F. JSON5 of the 30 tracked managers held BCAX at their latest 13F, $31.1M in total at quarter-end prices. D. E. Shaw & Co. is the largest at $14.8M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| D. E. Shaw & Co. | 2026-06-30 | 498K | $14.8M | 0.01% | +221K |
| Millennium Management | 2026-06-30 | 262K | $7.8M | 0.00% | +106K |
| Citadel Advisors | 2026-06-30 | 211K | $6.3M | 0.00% | -1.4M |
| Two Sigma Investments | 2026-06-30 | 47K | $1.4M | 0.00% | -43K |
| AQR Capital Management | 2026-06-30 | 30K | $888K | 0.00% | +17K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Bicara Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Bicara Therapeutics (BCAX), SEC CIK 2023658, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-21.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-07.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-11.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-08.JSON and CSV
- Company record
- EDGAR filing index for CIK 2023658Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of BCAX is sold short?
10,298,207 shares were held short at the 2026-10-15 settlement, 11.5 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is BCAX's daily short volume?
On 2026-11-02, 199,240 of the 1,030,541 BCAX shares reported to FINRA were sold short, 19.3% of the day's reported volume. Short volume is a flow for one day, not a position.
Does BCAX have fails to deliver?
The SEC's latest file shows 267 BCAX shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are BCAX insiders buying or selling?
Insiders at BCAX reported 5 open-market sells worth $1.6M in the last 90 days and no open-market buys. Latest filing: Cohlhepp Ryan (President, COO & Interim CEO) on 2026-09-08.
Have BCAX insiders filed to sell?
50 Form 144 notices on file for BCAX worth $15.8M at the prices reported; 6 in the last 90 days worth $2.3M. Latest: DAVID RABEN filed on 2026-10-21 to sell 24,777 shares ($449K) from 2026-10-21.
Who owns 5% or more of BCAX?
11 holders report 5% or more of BCAX in their latest filing, 4 on Schedule 13D (active intent). The largest reported stake is RA Capital Management, L.P. at 11.5% of the class (7,279,739 shares), filed 2026-03-02 for an event on 2026-02-26.
Which tracked 13F managers own BCAX?
5 of the 30 tracked 13F managers held BCAX shares at their latest filing, $31.1M in all. The largest: D. E. Shaw & Co. (498K shares, $14.8M), Izzy Englander's Millennium Management (262K shares, $7.8M), Ken Griffin's Citadel Advisors (211K shares, $6.3M), Two Sigma Investments (47K shares, $1.4M), Cliff Asness's AQR Capital Management (30K shares, $888K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.